Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
Posted in -
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Posted in -
Without Reform, Medicare Policies Will Hamstring New Gene Therapies
It took until the fall of 2020 for Medicare to consistently pay an adequate amount for CAR-T therapy. Now that same agonizing process awaits a raft of promising gene therapies in the pipeline – with lives in the balance – unless policymakers take action.
Posted in -
USC Schaeffer Center and Aspen Institute Advisory Panel Recommend Ways to Modernize Health Technology Assessment in the U.S.
The U.S. has no public organization dedicated to producing and evaluating HTAs despite the potential of HTAs providing critical input about price and value, while also recognizing the contribution of innovation to advancing health and healthcare.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Monthly Cost Sharing Doubles Throughout the Year for Some Medicare Insulin Users
Schaeffer Center researchers examined how use of insulin changes as cost-sharing fluctuates over the course of the year for Medicare Part D beneficiaries.
-
Paying for Cell and Gene Therapies in Medicare
Join Schaeffer Center Director Dana Goldman in conversation with Jeet Guram and Kathy Buto about policy lessons learned and potential solutions to support innovation and patient access in cell and gene therapies.
Categorized in -
Blood-Based Multicancer Tests Could Help Reduce Racial and Socioeconomic Cancer Health Disparities
Out of the 1.3 million individuals between the ages of 50-79 who are diagnosed with cancer, only 15% of those cases will be caught early. Aspen Institute and USC Schaeffer Center partnered for an expert discussion on early detection technologies.
-
Will the Rebate Rule need Extra Innings?
The publication of the final rebate rule is an important milestone in this administration’s drug pricing journey. However, many challenges remain.
Categorized in -
Sharing Drug Rebates With Medicare Part D Patients: Why And How
The percentage of total Medicare Part D drug spending offset by rebates on branded drugs increased from 11% in 2010 to 25% in 2018.
-
Are U.S. Health Care Prices Too High, Too Low, or Some Mix of the Two?
Part 1 of a panel series on health care price regulation honoring Uwe E. Reinhardt (1937-2017)
Categorized in